FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164839546> ?p ?o ?g. }

• W2164839546 endingPage "2815" @default.
• W2164839546 startingPage "2809" @default.
• W2164839546 abstract "PURPOSE The indications of adjuvant chemotherapy for patients with estrogen receptor (ER) -positive breast cancer are controversial. We analyzed the predictive value of Ki67, HER2, and progesterone receptor (PR) expression for the efficacy of docetaxel in patients with ER-positive, node-positive breast cancer. PATIENTS AND METHODS Expression of Ki67, HER2, and PR was measured by immunohistochemistry in tumor samples from 798 patients with ER-positive breast cancer who participated in PACS01, a randomized trial that evaluated the efficacy of docetaxel. Risk reduction was evaluated using a Cox model adjusted for age, tumor size, nodal involvement, treatment arm, and biomarkers. The predictive value of biomarkers was assessed by an interaction test. Disease-free survival (DFS) was the primary end point. Results Ki67, HER2, and PR were expressed in 21%, 9%, and 62% of samples, respectively. Hazard ratios for relapse associated with docetaxel were 0.51 (95% CI, 0.26 to 1.01) in ER-positive/Ki67-positive tumors and 1.03 (95% CI, 0.69 to 1.55) in ER-positive/Ki67-negative tumors (ratio for interaction: 0.53; 95% CI, 0.24 to 1.16; P = .11). Five-year DFS rates were 81% (95% CI, 76% to 86%) and 84% (95% CI, 75% to 93%) in patients with ER-positive/Ki67-negative and ER-positive/Ki67-positive tumors treated with docetaxel and 81% (95% CI, 76% to 86%) and 62% (95% CI, 52% to 72%) in patients with ER-positive/Ki67-negative and ER-positive/Ki67-positive tumors treated with fluorouracil, epirubicin, and cisplatin. No trend for interaction was observed between docetaxel and HER2 (ratio for interaction: 0.83; 95% CI, 0.35 to 1.94; P = .66), nor between docetaxel and PR (ratio for interaction: 0.89; 95% CI, 0.47 to 1.66; P = .71). CONCLUSION Ki67 expression identifies a subset of patients with ER-positive breast cancer who could be sensitive to docetaxel treatment in the adjuvant setting." @default.
• W2164839546 created "2016-06-24" @default.
• W2164839546 creator A5001029763 @default.
• W2164839546 creator A5001814176 @default.
• W2164839546 creator A5011227048 @default.
• W2164839546 creator A5013759812 @default.
• W2164839546 creator A5027832488 @default.
• W2164839546 creator A5036980881 @default.
• W2164839546 creator A5052648400 @default.
• W2164839546 creator A5061340891 @default.
• W2164839546 creator A5062385469 @default.
• W2164839546 creator A5062981484 @default.
• W2164839546 creator A5071021061 @default.
• W2164839546 creator A5083974898 @default.
• W2164839546 creator A5088324209 @default.
• W2164839546 creator A5091592799 @default.
• W2164839546 date "2009-06-10" @default.
• W2164839546 modified "2023-10-09" @default.
• W2164839546 title "Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer" @default.
• W2164839546 cites W1961026612 @default.
• W2164839546 cites W1965192399 @default.
• W2164839546 cites W2001968322 @default.
• W2164839546 cites W2008702365 @default.
• W2164839546 cites W2047179113 @default.
• W2164839546 cites W2075213874 @default.
• W2164839546 cites W2091205535 @default.
• W2164839546 cites W2110426068 @default.
• W2164839546 cites W2112894406 @default.
• W2164839546 cites W2115432999 @default.
• W2164839546 cites W2125835228 @default.
• W2164839546 cites W2127232551 @default.
• W2164839546 cites W2138605195 @default.
• W2164839546 cites W2141719586 @default.
• W2164839546 cites W2143865991 @default.
• W2164839546 cites W2144981148 @default.
• W2164839546 cites W2156604663 @default.
• W2164839546 cites W2160377567 @default.
• W2164839546 cites W2165727718 @default.
• W2164839546 cites W2167926320 @default.
• W2164839546 cites W2466792968 @default.
• W2164839546 cites W4237049413 @default.
• W2164839546 doi "https://doi.org/10.1200/jco.2008.18.2808" @default.
• W2164839546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19380452" @default.
• W2164839546 hasPublicationYear "2009" @default.
• W2164839546 type Work @default.
• W2164839546 sameAs 2164839546 @default.
• W2164839546 citedByCount "209" @default.
• W2164839546 countsByYear W21648395462012 @default.
• W2164839546 countsByYear W21648395462013 @default.
• W2164839546 countsByYear W21648395462014 @default.
• W2164839546 countsByYear W21648395462015 @default.
• W2164839546 countsByYear W21648395462016 @default.
• W2164839546 countsByYear W21648395462017 @default.
• W2164839546 countsByYear W21648395462018 @default.
• W2164839546 countsByYear W21648395462019 @default.
• W2164839546 countsByYear W21648395462020 @default.
• W2164839546 countsByYear W21648395462021 @default.
• W2164839546 countsByYear W21648395462022 @default.
• W2164839546 countsByYear W21648395462023 @default.
• W2164839546 crossrefType "journal-article" @default.
• W2164839546 hasAuthorship W2164839546A5001029763 @default.
• W2164839546 hasAuthorship W2164839546A5001814176 @default.
• W2164839546 hasAuthorship W2164839546A5011227048 @default.
• W2164839546 hasAuthorship W2164839546A5013759812 @default.
• W2164839546 hasAuthorship W2164839546A5027832488 @default.
• W2164839546 hasAuthorship W2164839546A5036980881 @default.
• W2164839546 hasAuthorship W2164839546A5052648400 @default.
• W2164839546 hasAuthorship W2164839546A5061340891 @default.
• W2164839546 hasAuthorship W2164839546A5062385469 @default.
• W2164839546 hasAuthorship W2164839546A5062981484 @default.
• W2164839546 hasAuthorship W2164839546A5071021061 @default.
• W2164839546 hasAuthorship W2164839546A5083974898 @default.
• W2164839546 hasAuthorship W2164839546A5088324209 @default.
• W2164839546 hasAuthorship W2164839546A5091592799 @default.
• W2164839546 hasBestOaLocation W21648395461 @default.
• W2164839546 hasConcept C121608353 @default.
• W2164839546 hasConcept C126322002 @default.
• W2164839546 hasConcept C143998085 @default.
• W2164839546 hasConcept C207103383 @default.
• W2164839546 hasConcept C2776694085 @default.
• W2164839546 hasConcept C2780835546 @default.
• W2164839546 hasConcept C2781190966 @default.
• W2164839546 hasConcept C29456083 @default.
• W2164839546 hasConcept C44249647 @default.
• W2164839546 hasConcept C530470458 @default.
• W2164839546 hasConcept C71924100 @default.
• W2164839546 hasConcept C84606932 @default.
• W2164839546 hasConceptScore W2164839546C121608353 @default.
• W2164839546 hasConceptScore W2164839546C126322002 @default.
• W2164839546 hasConceptScore W2164839546C143998085 @default.
• W2164839546 hasConceptScore W2164839546C207103383 @default.
• W2164839546 hasConceptScore W2164839546C2776694085 @default.
• W2164839546 hasConceptScore W2164839546C2780835546 @default.
• W2164839546 hasConceptScore W2164839546C2781190966 @default.
• W2164839546 hasConceptScore W2164839546C29456083 @default.
• W2164839546 hasConceptScore W2164839546C44249647 @default.
• W2164839546 hasConceptScore W2164839546C530470458 @default.
• W2164839546 hasConceptScore W2164839546C71924100 @default.

• next